- CH₣36.26bn
- CH₣37.78bn
- CH₣6.72bn
- 67
- 11
- 83
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 36.9 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -1.8% | ||
| Dividend Yield (f) | 0.92% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.84 | ||
| Price to Tang. Book | 7.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.4 | ||
| EV to EBITDA | 25.17 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.25% | ||
| Return on Equity | 6.52% | ||
| Operating Margin | 13.1% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | 4,207 | 4,508 | 5,409 | 6,223 | 6,717 | 6,654.57 | 7,581.22 | 3.92% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -3.71 | +8.93 | +16.63 | +17.26 | -1.12 | -11.98 | +24.69 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
Directors
- Albert Baehny CHM (69)
- Pierre-Alain Ruffieux CEO (52)
- Rodolfo Savitzky CFO (59)
- Caroline Barth CHO (49)
- Stefan Stoffel EXB (55)
- Christoph Maeder LED (61)
- Werner Bauer IND (71)
- Dorothee Deuring IND (52)
- Angelica Kohlmann IND (61)
- Barbara Richmond IND (60)
- Juergen Steinemann IND (63)
- Olivier Verscheure IND (49)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 27th, 2002
- Public Since
- April 3rd, 2002
- No. of Shareholders
- 51,720
- No. of Employees
- 18,000
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
SIX Swiss Exchange- Shares in Issue
- 72,116,589
- Address
- Muenchensteinerstrasse 38, BASEL, 4002
- Web
- https://www.lonza.com/
- Phone
- +41 613168111
- Auditors
- KPMG AG
Latest News for LONN
Upcoming Events for LONN
Lonza Group AG Annual Shareholders Meeting
Lonza Group AG Annual Shareholders Meeting
Dividend For LONN.S - 2.0000 CHF
Dividend For LONN.S - 2.0000 CHF
Half Year 2024 Lonza Group AG Earnings Release
Similar to LONN
Addex Therapeutics
SIX Swiss Exchange
BACHEM HOLDING AG
SIX Swiss Exchange
Basilea Pharmaceutica AG Allschwil
SIX Swiss Exchange
BB Biotech AG
SIX Swiss Exchange
Evolva Holding
SIX Swiss Exchange
FAQ
As of Today at 19:13 UTC, shares in Lonza AG are trading at CH₣502.80. This share price information is delayed by 15 minutes.
Shares in Lonza AG last closed at CH₣502.80 and the price had moved by -11.7% over the past 365 days. In terms of relative price strength the Lonza AG share price has underperformed the FTSE Global All Cap Index by -17.1% over the past year.
The overall consensus recommendation for Lonza AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Lonza AG dividend yield is 0.8% based on the trailing twelve month period.
Last year, Lonza AG paid a total dividend of CH₣4.00, and it currently has a trailing dividend yield of 0.8%.Looking ahead, shares in Lonza AG are due to go ex-dividend on 2024-05-13 and the next dividend pay date is 2024-05-15.
Lonza AG are due to go ex-dividend on 2024-05-13 and the next dividend pay date is 2024-05-15. The historic dividend yield on Lonza AG shares is currently 0.8%.
To buy shares in Lonza AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣502.80, shares in Lonza AG had a market capitalisation of CH₣36.26bn.
Here are the trading details for Lonza AG:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: LONN
Based on an overall assessment of its quality, value and momentum Lonza AG is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Lonza AG is CH₣553.10. That is 10% above the last closing price of CH₣502.80.
Analysts covering Lonza AG currently have a consensus Earnings Per Share (EPS) forecast of CH₣12.68 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lonza AG. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +31.38%.
As of the last closing price of CH₣502.80, shares in Lonza AG were trading +16.15% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lonza AG PE ratio based on its reported earnings over the past 12 months is 36.9. The shares last closed at CH₣502.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lonza AG's management team is headed by:
- Albert Baehny - CHM
- Pierre-Alain Ruffieux - CEO
- Rodolfo Savitzky - CFO
- Caroline Barth - CHO
- Stefan Stoffel - EXB
- Christoph Maeder - LED
- Werner Bauer - IND
- Dorothee Deuring - IND
- Angelica Kohlmann - IND
- Barbara Richmond - IND
- Juergen Steinemann - IND
- Olivier Verscheure - IND